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Chairperson: Fernando Cardozo-Pelaez, Ph.D. 
 
Parkinson’s disease (PD) is the second most common neurodegenerative 
disorder with no known specific cause; although genetic risk factors and/or 
environmental exposure are thought to be involved.  The etiology of PD is 
currently unknown, although the combination of non-genetic components such as 
environmental exposures, the accumulation of exposure, and gene-environment 
interactions are thought to play a major role.  However, despite this knowledge it 
is important to develop better models that parallel PD pathophysiology to further 
understand the mechanisms underlying dopaminergic neuron (DaN) damage. 
The use of mammalian models to study the degenerative processes in PD has 
been the most common approach. However, Drosophila melanogaster use has 
proven to be important to identify the physiological role of PD associated genes, 
and to identify pathological mechanisms of environmental toxins associated with 
sporadic PD.  The synthetic drug MPTP (1-methyl- 4-phenyl-1,2,3,4-
tetrahydropyridine) has been extensively used to generate animal models of PD. 
MPTP is the most used toxin model with highly reproducible effects in mice and 
non-human primates, and its use is a requirement for the development of new 
therapeutic approaches.  However, MPTP neurotoxicity has not been reported in 
D. melanogaster.  Results from the studies presented in this thesis show that 
Drosophila exposure to MPTP may be a useful model of PD, as evidenced by: 
loss of brain DA, reduction in tyrosine-hydroxylase positive neurons and inhibition 
of mitochondrial complex I. Thus, taken together this recapitulates the 
mammalian model  
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CHAPTER ONE: INTRODUCTION 
 This study describes the characterization of an MPTP-toxin induced model 
of Parkinson’s disease in Drosophila melanogaster, or fruit fly.  The introductory 
chapter will: 1) Present an overview of PD and current therapies; 2) Discuss PD 
genetics and the etiology of the disease; 3) Explain the pathophysiology of PD 
and the role of mitochondria; and 4) Provide information on current models of PD 
and how they contribute to our understanding of PD. 
Overview to Parkinson’s Disease  
Parkinson’s Disease (PD) is the second most common neurodegenerative 
disease after Alzheimer’s Disease (AD).  Currently, seven to ten million people 
worldwide are diagnosed with PD with a higher percentage of patients being 
older than 65 years of age and this percentage is estimated to continue to rise 
(Parkinson’s disease Foundation).  Clinically, several symptoms are manifested 
in PD that can be classified as motor and non-motor.  Motor symptoms include: 
resting tremor, rigidity, bradykinesia, and postural instability.  These motor 
symptoms are the most noticeable and are diagnosed based on at least one of 
these symptom criteria: muscular rigidity, a resting tremor of at least 4-6 Hz, 
patient history, and exclusion of other disease symptoms (Worth 2013).  Non-
motor symptoms can accompany motor symptoms and are often the most 
impacting on the quality of life in patients, which include: autonomic insufficiency, 
cognitive impairment, and sleep disorders.  Non-motor symptoms are unique in 
that they may be evident earlier in the disease and before motor symptoms.  
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Demonstrating their impact on quality of life of patients, these non-motor 
symptoms are the major determining factor for assisted care of patients.  
The pathophysiology of this chronic progressive disease is characterized 
by the loss of dopaminergic neurons in the substantia nigra with the presence of 
Lewy bodies (LBs), which are proteinaceous, α-synuclein-containing inclusions 
within the surviving dopaminergic neurons (DaN).  α-Synuclein is a normal 
endogenous protein in the brain that has a suggested role in synaptic vesicular 
trafficking (Overk and Masliah 2014).  Although much has been done to 
understand the mechanisms underlying the pathophysiology, the cause of PD is 
still unknown. The most current hypothesis suggests that interplay between 
genetic predispositions and environmental exposures underlay cause on the 
onset of idiopathic PD. 
 The diagnosis of PD still relies on clinical skill of the patient’s physician to 
make a diagnosis based on the UK PD brain bank diagnostic criteria (Dickson et 
al. 2009). There are currently no selective biomarkers to make a definitive 
diagnosis, let alone, before symptoms are overt.  As mentioned before, diagnosis 
is based on the presence or absence of bradykinesia (the slowness of voluntary 
movement), and at least one of the other motor symptoms listed previously.  The 
diagnostic standard also includes exclusion criteria (i.e history of strokes, head 
injury, etc.), additional supportive criteria (i.e Levodopa response, disease 
progression, etc.), and neuropathological presence of neuronal loss and LBs 
(Obeso et al. 2010).  Although, despite neuronal loss and LBs having a part in 
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diagnosis, there is no definitive protocol for this type of assessment thus 
generating a need for better diagnostic imaging of the brain and biomarkers.    
Currently PD is incurable and it progresses at different rates depending on 
the individual.  There are several treatments for patients with PD, but it is 
important to note that these treatments only treat the symptoms of PD rather than 
tackling the pathophysiology causing the neuronal loss.  Treatment for PD can be 
divided into two types based on the symptoms they are treating, motor and non-
motor.  The timing of initiation of these therapies is still debated.  Most patients 
are left untreated until developing a disability that impacts their quality of life, 
whereas some studies report dopaminergic drug therapy before disability 
presence showing improvement of quality of life (Grosset et al. 2007). 
 The most common drug treatment for motor symptoms is Levodopa, or L-
dopa.  In combination with a dopamine carboxylase inhibitor, L-dopa remains the 
most efficacious treatment for PD motor symptoms for the last 60 years (LeWitt 
2008).  L-dopa is the precursor for dopamine, therefore is effective by 
replenishing dopamine in surviving neurons.  One of the major side effects of L-
dopa treatment is L-dopa induced dyskinesia’s (LIDs), which involve dramatic 
involuntary chorea movements that can be more debilitating to patients than the 
motor symptoms themselves.  Typically L-dopa therapy is not used in patients 
under the age of 50 due to a reduced response consistency over time of use, but 
it is still a first line of treatment in patients of all ages (Ku and Glass 2010). 
Dopamine agonists (DAs) are another used group of drugs intended to 
activate the dopamine receptor in the absence of dopamine for treatment of 
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motor symptoms.  These sets of drugs are typically used as a first line of defense 
for early PD, similar to L-dopa.  Also similar to L-dopa, DAs are associated with 
side effects termed impulse control disorders (ICDs).  ICDs occur in 17% of 
patients that can range in symptoms including hypersexuality, compulsive 
gambling, shopping and eating (Voon, Mehta, and Hallett 2011). 
Monoamine oxidase B (MAO-B) inhibitors, which inhibit the enzymatic 
breakdown of neurotransmitter amines (dopamine), have limited use for 
treatment of PD but, are found to reduce mild tremor symptoms in patients.  
Along with the lesser-used MAO-B inhibitors, anticholinergic drugs are 
occasionally used for patient’s symptoms predominantly having tremors, 
although their efficacy is hampered by its neuropsychiatric side effects in some 
patients.  Pharmacological therapies for non-motor symptoms mentioned are 
minimal, thus leaving a need for development strategies to abate these 
symptoms.   
In most patients, the combinational therapies of drugs discussed above 
are used for individualized treatment in patients.  As the disease progresses, 
pharmacological therapy is less effective leaving exploration of other forms of 
treatment including non-pharmacological therapies.  Non-pharmacological 
therapies include options such as deep-brain stimulation (DBS) and physical 
therapy.  DBS is generated by trends of high-frequency electrical impulses 
delivered to the subthalamic nucleus or globus pallidus interna mitigating the side 
effects of medications or allowing for reduction of medication dose (Carron et al. 
2013).  Despite these treatments, there is still a need for therapies aiming for 
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neuro-protection and neuronal restoration, and the development of models for 
capturing the disease pathology and symptoms to evaluate such therapeutic 
approaches.    
Genetics of Parkinson’s Disease 
Monogeneic inheritable forms of PD are thought to account for less than 10% of 
all cases and of these cases only a few follow Mendelian inheritance patterns. 
Despite representing a smaller portion of PD cases, familial inheritance studies 
have revealed 15 PD loci (PARK 1-15) with 11 of these PARK loci that have 
been described (TABLE 1).  In addition to familial genes known to cause PD 
there are also known genes associated with sporadic PD (of no known cause) 
(TABLE 2) as well as variants of each of these genes that can also contribute to 
disease and/or individual susceptibility. 
 Familial PD genetics can be divided into two groups: autosomal dominant 
loci and autosomal recessive loci.  Autosomal dominant loci include mutations in 
the α-synuclein gene (SNCA), PARK1 and PARK 4 and LRRK2/PARK8 (Lesage 
and Brice 2012).  There are also other dominant genes described; yet, these are 
controversial and have not been replicated (UCHL1/PARK5), GRB10- interacting 
GYF protein 2 (GIGYF2/PARK11), Omi/Htra2 (PARK13).  The SNCA gene codes 
for a component of the amyloid precursor protein and is thought to be 
responsible for membrane trafficking and synaptic signaling and when 
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TABLE 1.  15 PD loci associated with familial inheritance 
 
Adapted from (Coppedè 2012) 
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TABLE 2. Parkinson’s Disease-associated genes 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Adapted from (Abou-Sleiman, Muqit, and Wood 2006)  
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 present with a mutation causes functional and structural abnormalities and the 
formation of LBs (Puschmann 2013).  Mutations of SNCA can be either missense 
or point-mutations with a mutation frequency of about 1% (Irwin, Lee, and 
Trojanowski 2013).  Phenotypically, SNCA mutations resemble sporadic PD 
patients with the presentation of earlier onset and atypical features, including 
cognitive decline, psychiatric problems and autonomic dysfunction (Singleton, 
Farrer, and Bonifati 2013). 
Another common autosomal dominant mutation is in LRRK2, which is 
associated with young-onset familial (~10%) and late-onset sporadic PD (~2%) 
(Krüger 2008).  LRRK2 protein’s role in dopaminergic cell death is unknown but it 
is thought to be due to a decrease in its kinase activity (Wickremaratchi, Ben-
Shlomo, and Morris 2009).  
 Genes associated with autosomal recessive forms of PD include: Parkin: 
PARK2, PTEN-Induced Putative Kinase 1 Gene (PINK-1): PARK6, DJ-1: PARK7, 
and ATP13A2 Gene: PARK9.  Typically, PD cases due to these genes appear in 
offspring of unaffected parents due to their inheritance pattern, therefore 
sometimes determined sporadic due to its lower frequency (Lin and Farrer 2014).  
Typically these alleles result in loss of function due to inactive protein and/or 
absence of protein synthesis. 
 Parkin mutations account for the majority of autosomal recessive cases in 
patients and there are approximately 170 different mutations possible on the 
chromosome (Mata, Lockhart, and Farrer 2004).  Parkin mutations are 
characterized by early onset of disease without the presence of LBs.  Parkin is 
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thought to be responsible for mitochondrial-induced apoptosis through 
unregulated release of cytochrome c. 
PTEN-induced putative kinase 1 (PINK-1) is also an autosomal recessive 
mutation on a different chromosome from the Parkin mutations.  The PINK-1 
mutations are responsible for mitochondrial deficits, therefore leading to 
mitochondrial dysfunction.  Typically, PINK1 is involved in mitochondrial 
maintenance participating in an upstream pathway in mitochondrial autophagy 
(Kawajiri et al. 2011).  Similar to PINK-1, which responds to mitochondrial 
alterations, DJ-1 (PARK7) responds to changes in oxidative stress environment 
for mitochondrial protection.  This response action causes DJ-1 to bind to PINK1 
to promote degradation by the ubiquitin proteasome system (UPS) by damaged 
parkin proteins.  Mutations in the ATP13A2 Gene (PARK 9) lead to pathologies 
that resemble idiopathic PD.  The protein coded by PARK 9 is thought to be 
involved in homeostasis of manganese (Chesi et al. 2012).  The other PARK loci 
are thought to be mainly involved in the UPS system and disruption of this 
protein homeostatic pathway.  
Overall, genetics play an important role in PD pathology and have helped 
our understanding of the pathological pathways linked to the neurodegenerative 
process.  As shown in Figure 1, the interplay between environment and genetics 
is the basis of the current hypothesis of etiology of PD pathology.  However, 
whether it is a specific environmental agent or family of agents; as well as which 
genes are more relevant for the development of the idiopathic form of PD needs 
to be fully determined.  In addition to genetics, epigenetic mechanisms are 
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thought to have a key role in modulating the risk of PD development; this is 
supported by findings of differential methylation patterns in some of the genes 
discussed above (e.g LRRK2, SNCA). 
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FIGURE 1 
 
 
 
 
 
 
 
 
Adapted from (Krüger 2008) 
 
Figure 1.  Penetrance of PD and susceptibility factors   
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Etiology of Parkinson’s Disease 
The exact etiology of PD is unknown; however, there are hypothesis about 
what contributes to the different forms of the disease. One of the hypotheses 
suggests a major genetic component for the development of early-onset forms, 
while the late-onset forms are mostly due to environmental factors.  It is believed 
that the link between these two types of hypothesis is at the root of the cause 
and the mechanism linked to the dopaminergic neuronal death. Three common 
endogenous factors, dopamine, alpha-synuclein, and calcium, are linked to five 
different mechanisms of DaN degeneration. The first mechanism involves 
generation of oxidative stress through the oxidation of cytosolic dopamine.  The 
second mechanism is initiated by the release of dopamine due to synaptic 
vesicle permeabilization from mutations and/or excessive alpha-synuclein.   The 
third mechanism is through dopamine binding to alpha-synuclein protofibrils, 
allowing them to be a persistent toxic species.  The fourth proposed mechanism 
is driven by increased intracellular calcium leading to the dysfunction of the 
mitochondria.  The fifth mechanism is the inhibition of the lysosomal degradation.    
Figure 2 illustrates the possible interactions between endogenous factors, 
environment, and genes, with the possible outcomes leading to pathology seen 
in PD.  This best summarizes the most current hypothesis for the etiology of PD, 
taking into account all these factors and how they may interplay. Thus, 
determining a direct explanation or identifying a single cause, is a complicated 
endeavor. 
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FIGURE 2 
 
 
 
 
 
 
Adapted from (Fahn 2010) 
 
Figure 2. Etiologic Factors Involved in Parkinson’s disease  
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Role of Mitochondria in Dopaminergic Cell Death 
Mitochondrial dysfunction has been implicated as a key component to PD 
pathogenesis. Additionally, the discovery of toxins such as, MPTP (1-methyl- 4-
phenyl-1,2,3,4-tetrahydropyridine) has further implicated the role of 
environmental toxins and that of mitochondria dysfunction in PD.  The link 
between mitochondria dysfunction and PD was first suggested when it was 
shown that patients with PD had decreased complex I activity in the substantia 
nigra, skeletal muscle and platelets (Mizuno et al. 1989), and further supported 
by identifying that the major mitochondrial Complex I inhibition is a common 
mechanism linked to dopaminergic toxins (Banerjee et al. 2009). 
 MPTP enters the brain by crossing the blood-brain barrier where it is converted 
to MPP+ by the enzyme monoamine oxidase B.  MPP+ then binds to the 
dopamine transporter and is transported into neurons. Inside the neurons MPP+ 
has a high affinity for the complex I of the electron transport chain (ETC), 
inhibiting respiration.  This inhibition of the ETC induces a build-up of free radical 
production, oxidative stress, decreased ATP production, subsequent release of 
intracellular calcium, and excitotoxicity.  Furthermore, it has been shown that 
MPP+ releases dopamine leading to increased oxidative stress (Carta, Carboni, 
and Spiga 2013). 
 The complete picture of mitochondrial involvement with PD began after 
the discovery of familial genes of PD. As mentioned in the section discussing 
genetics and PD, many of the familial genes associated with PD have some role 
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in physiological pathways that directly or indirectly are associated with the 
mitochondria; thus, inferring that normal mitochondria function is a major factor in 
promoting DaN viability (Chesselet and Richter 2011). Figure 3 depicts the 
accepted mechanism for dopaminergic neurotoxicity associated with MPTP, 
while Figure 4 illustrates the purported role in mitochondrial dysfunction and 
oxidative stress of some of the genes implicated in familial forms of PD. 
  
	   16	  
FIGURE 3 
 
 
 
 
 
 
 
 
 
Adapted from (Vila and Przedborski 2003) 
 
Figure 3.  MPTP Inhibition of Mitochondrial complex I   
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FIGURE 4 
 
 
 
 
 
 
 
 
 
 
Adapted from (Abou-Sleiman, Muqit, and Wood 2006) 
 
Figure 4. Genes Involved in Mitochondrial Dopaminergic cell death   
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Toxin-Induced Models of Parkinson’s Disease 
The current knowledge and advancements in the field of PD can be attributed to 
the use and discovery of PD models.  Although there are many models available, 
as will be discussed, there are unique characteristics linked to toxicological 
mechanism, exposure, and progression of damage that would make a model 
more suitable than others to answer a specific question (Beal 2001).  First, the 
main characteristic of PD pathology is the gradual loss of dopaminergic neurons 
and the age-dependent formation of LBs.  For any model, a loss of dopamine of 
about 50%, should be detectable by biochemical and neuropathology.  Second, 
the model should link dopamine loss and motor-deficits; thus, reenacting the 
classical hallmarks of the disease (bradykinesia, resting tremor, and postural 
rigidity) (Blesa et al. 2012).  Finally, tying the model to a single mutation is 
important to discover disease etiology.  Currently, there is not a single model that 
combines the major risk factors of PD.  A generation of such model may allow for 
shorter time for evaluation of experimental therapies and to assess the effect of 
the aging process.  
 The use of dopaminergic toxins in vertebrates is the most common 
approach to model the neuronal loss in PD.  Toxin-induced models include: 6-
hydroxydopamine (6-OHDA), rotenone, and MPTP.  Figure 5 depicts the most 
accepted mechanism for each of these toxin-induced models.  6-OHDA is used 
in rats, mice, and primates by direct injection into the substantia nigra, usually 
generating a unilateral lesion (Harvey, Wang, and Hoffer 2008).  Although, LBs 
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are not present, there is a loss of targeted DaNs that can lead to a reduction in 
motor abilities (Tieu 2011). 
 Rotenone is a pesticide that is still used in the fishing industry today.  
Rotenone is a selective inhibitor of mitochondrial complex I.  Chronic treatment 
with rotenone has replicated the specificity of dopaminergic nigral neuron loss in 
rodents, and is the only toxicological model to generate LBs.  This model, 
however, is not widely used due to the variability and lack of consistency of the 
neuropathological changes (Lapointe et al. 2004)(Zhu et al. 2004). 
 MPTP is the most common used toxin to generate a PD model.  As 
discussed in the previous section, it was one of the first models to link the 
inhibition of mitochondria complex I and PD.  Although several animal species 
have been treated with MPTP to recapitulate the model (sheep, dogs, guinea 
pigs, cats, mice, rats, and monkeys), the MPTP-monkey model is still the 
standard for testing of therapeutic interventions (Carta, Carboni, and Spiga 
2013).  Both monkeys and mice treated with MPTP have selective progressive 
loss of nigrostriatal DaN, reproducible motor deficits, but no LBs (Tieu 2011). 
Table 3 (excluding paraquat/maneb) summarizes the current toxin-
induced models and what characteristics are present in each one.  Having these 
models as the current standards has been beneficial, although the need for a 
better model that is cheaper, faster to screen therapeutic interventions, and 
accessible is necessary. 
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Figure 5 
 
 
 
 
 
 
 
 
 
 
 
Adapted from (Abdel-Aal, Assi, and Kostandy 2011) 
 
Figure 5. Mechanisms of Toxin-Induced Models of Parkinson’s disease 
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Table 3. Toxin-Induced Models of Parkinson’s disease 
 
 
 
Adapted from (Tieu 2011)  
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The use of Drosophila melanogaster as a neurodegenerative model 
Using Drosophila melanogaster as a model for neurodegenerative processes has 
become increasingly popular, especially in the field of PD.  The current models of 
PD do not include all the major risk factors linked to the pathological processes 
observed in the disease, whereas Drosophila models are amiable to incorporate 
most of them and may fill this need (Guo 2012).  The use of an invertebrate 
model has many advantages over traditional vertebrate models, such as: short 
lifespan, ease of genetic manipulation, and a conserved DA neurotransmitter 
system.  The drosophila genome has limited redundancy and is 77% 
homologous to humans (Rubin 2011).  Therefore, studying familial genes 
associated with PD (DJ-1, PINK1, PARKIN, LRRK2, and VPS35) and their role in 
pathogenesis in the fly is possible. 
 In addition to genetic forms of PD, toxin-induced models of PD in 
Drosophila are becoming useful tools.   Several studies have looked at rotenone 
and paraquat (PQ) (a proposed mitochondrial complex I inhibitor) in Drosophila 
to investigate susceptibility of PD genetic models and its role in neuronal cell 
death (Botella et al. 2009).  Not only do these models induce loss DaNs, but also, 
there is evidence of behavioral and histological changes, completing the 
pathological picture of PD (Trinh et al. 2010).  Despite studies in Drosophila 
examining rotenone and paraquat, as models, there are no studies with MPTP in 
drosophila. 
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 The hypothesis tested and presented is that wild-type Drosophila 
melanogaster will be susceptible to MPTP and will generate a robust model with 
classical signs of PD pathology as defined by loss of dopamine, tyrosine 
hydroxylase-positive neurons, and motor behavior deficits.  Therefore, we want 
to determine how MPTP, implicated in other PD models, impacts 
pathophysiology and toxicity in Drosophila in the following two aims: 
Specific Aim 1: To define the time- and dose-course susceptibility to MPTP 
dopaminergic neurotoxicity in Drosophila. 
Specific Aim 2: To correlate inhibition of mitochondrial Complex I with loss of the 
dopaminergic system in Drosophila.  
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CHAPTER TWO: AIM ONE 
Defining the dose susceptibility to MPTP dopaminergic neurotoxicity in 
Drosophila melanogaster: Analysis of PD pathological markers after toxin 
exposure 
Abstract 
Drosophila melanogaster has become a useful tool for assessing models of PD.  
The use of toxin-induced models, such as rotenone and paraquat, has been 
investigated in Drosophila, but MPTP has not been tested.  This chapter 
describes a method for MPTP exposure in Drosophila and investigates 
biochemical and pathological markers associated with PD.  Exposure to MPTP 
reduced dopamine in brains of male flies and altered behavior assessed by 
startle-induced negative geotaxis. 
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Introduction 
Models of Parkinson’s disease (PD) are important in the discovery of the 
pathophysiology of the disease.  Although there are several animal models 
looking at familial genetic mutations that have roles in the disease pathways, 
models portraying idiopathic PD, which are the majority of disease cases, are 
critical in discovery of mechanisms. 
 Drosophila melanogaster (fruit fly) has been increasingly useful in PD 
modeling.  More specifically, Drosophila has been used for investigating rotenone 
and paraquat (PQ), both of which are commonly used for modeling idiopathic PD.  
Recently, rotenone has been used in several studies examining PD pathology 
markers including: histology and behavioral assessment (Hosamani, Ramesh, 
and Muralidhara 2010).  PQ exposure in Drosophila has also been established in 
some studies for acute and chronic exposure (Rzezniczak et al. 2011) (Lawal et 
al. 2010).  Despite both of these models showing pathologic markers seen in PD, 
there are several inconsistencies with both the rotenone and paraquat models in 
other animals used (Vila and Przedborski 2003).  These types of inconsistencies 
include: low percentage of rats exposed showing nigrostriatal lesions, rotenone is 
specific to rats and does not work in other animal models, and there are no 
reported human toxicity exposures resulting in PD (Nussbaum and 
Polymeropoulos 1997).  Similarly, results with paraquat, remain inconsistent due 
to conflicting reports in relationship to the susceptibility of dopaminergic neurons 
after exposure, or whatever PQ combination with maneb (manganese 
ethylenebisdithiocarbamate) is a more effective model (Thiruchelvam et al. 2000) 
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(Thiffault, Langston, and Di Monte 2000).  MPTP has been used in animal 
models of genetic forms of PD, contributing to the identification role(s) these 
genes play in pathophysiology.  Therefore, the most common and highly 
researched and reproducible toxin-induced model, MPTP, should be developed 
in the fruit fly. 
 The following study describes an analysis of PD pathological markers in 
Drosophila males after MPTP exposure.  Although Drosophila has been used as 
a model for rotenone and paraquat toxicity, the MPTP model has yet to be 
investigated.  Optimization of the CAFÉ assay with MPTP was achieved by 
spectrophotometry and measurement of consumption.  The method described 
here was used to analyze dopamine in brain of flies exposed to increasing 
concentrations of MPTP and to assess behavior and tyrosine hydroxylase 
expression after exposure.  Our results indicate that acute MPTP exposure leads 
to a dose-dependent loss of dopamine, a trend in reduction of TH-positive 
neurons and alterations in motor behavior in flies. Thus, these results indicate 
that the MPTP toxin-induced model in Drosophila melanogaster is a useful tool to 
use for pathophysiology in PD. 
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Materials and Methods 
Chemicals and Reagents 
 All reagents were purchased from Sigma Aldrich unless otherwise 
indicated (St Louis, MO).  MPTP were made fresh for each exposure with 5% 
sucrose w/v. 
Drosophila Stocks, Husbandry, and transgenics 
 D. melanogaster wild-type (Canton-S) was obtained from the Bloomington 
Stock center (Bloomington, IN).  The flies were reared on agar medium (1%, w/v 
brewer’s yeast; 2%, w/v sucrose; 1%, w/v agar; 0.08%, v/w Tegosept®) at 
constant temperature and humidity (23°C; 60% relative humidity, respectively). 
The flies were reared in 16 x 100 mm vials containing approximately 5 mL of 
medium at constant temperature, humidity (60%) and under 12h dark/light cycle. 
All experiments were performed with the same WT Canton-S strain except for 
Immunohistochemistry. 
 Crosses to generate the TH-Gal4:20xUAS-6xGFP (green fluorescent 
protein) flies were set up under standard conditions at 25° C.  Male flies 
containing the TH-Gal4 UAS transcript were mated with females containing the 
20x-6xGFP insert, then pupae were collected into isolation vials. 
Drosophila MPTP exposure 
 The capillary feeder method (CAFE) CAFÉ assay used for exposure was 
adapted from JA, et al. 2007 (Ja et al. 2007).  The exposure model used was 
similar with two chambers.  The inner chamber, containing the flies, was 
composed of a 25 cm vial with perforated lid for air and water exchange from the 
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outer chamber, a 1000 mL beaker with 20 cm distilled water, and additional holes 
for capillary tube insertion.  Capillary tubes at 40 cm length from World Precision 
Instruments (Sarasota, FL) (cat. #4878) were filled by capillary action with liquid 
and inserted into the inner vial lid with an additional layer of mineral oil to prevent 
evaporation.  All exposures (MPTP or sucrose control) were conducted for 24 
hours in a 25°C room.  After each 24-hour exposure, flies were placed back into 
isolation vials containing normal food medium for 24 hours before analyses.  All 
exposures were done on 5-10 day old males including flies for immunohistology. 
Brain dopamine via HPLC-ED 
For sample preparation, fifteen 5-10 day old adult male flies were anesthetized 
with CO2, and then transferred to cold phosphate buffer saline (PBS) preceding 
dissection. Brains were dissected in cold PBS by gentle forceps manipulation 
under a dissecting microscope, and then transferred to a 1.5 ml microcentrifuge 
tube containing 100 µL perchloric acid (0.05 M) with 30 ng/mL DBA (internal 
standard).  On ice, brains were homogenized using a hand-held sonicator and 
centrifuged for 15 minutes at 4°C at 14,000xg. 
For reverse-phase high liquid chromatography (rp-HPLC) measurement of 
dopamine, a modified rp-HPLC protocol for catecholamine measurement was 
used as described earlier (F. Cardozo-Pelaez et al. 1999) (Fernando Cardozo-
Pelaez, Cox, and Bolin 2005). Chilled fly brain homogenates were centrifuged 
and 50 µl of supernatant fluid was eluted through a 250 × 4.6 mm C18 column 
(Agilent Technologies Santa Clara, CA). The mobile phase consisted of 
water:acetonitrile (9:1, vol/vol) containing 0.15 M monochloroacetic acid, 0.12 M 
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sodium hydroxide, 0.60 mM EDTA, and 1.30 mM sodium octyl sulfate.  The flow 
rate was kept at .8 mL/min (ESA Model 582 Solvent Delivery Module, 
Chelmsford, MA) and the column eluent was analyzed with an electrochemical 
detector (ESA Model 5600A CoulArray Detector, 3 ESA Model 6210 four channel 
electrochemical cells, Chelmsford, MA -50, 0, 100, 200, 300mV). All RP-HPLC 
data were recorded stored and analyzed using CoulArray for Windows 
32Software (ESA Chelmsford, MA).  DA was monitored at 300mV. The ratios of 
peak height measured in Nano amperes (nA) produced by DA to the peak height 
(nA) produced by DBA (internal standard) in the samples were used to obtain the 
analyte levels from a calibration curve. Data was expressed as micrograms of 
analyte per brain (µg/brain). 
Immunohistology & Confocal Imaging 
For immunohistochemistry; after cuticle was removed, the brains were fixed in 
4% paraformaldehyde.  Confocal microscopy image processing was performed 
using a Olympus IX81 confocal microscope and Fluoview FV1000 viewer and 
application software.  Antibody dilutions were as follows: rabbit anti-Tyrosine 
Hydroxylase 1:200 (Abcam) and Goat anti-rabbit 594 1:200 (Abcam).  Images 
were acquired at a resolution of 1024 pixels. The counting of DA neurons labeled 
with TH:GFP and 594 labeling were tracked through confocal Z-stacks. 
Startle-Induced Negative Geotaxis 
To assess locomotor climbing activity, we transferred into empty plastic vials 30-
50 male flies that had been exposed to MPTP or 5% sucrose were transferred 
into empty 50 mL conical tubes.  Flies were allowed to acclimate in the vial for 15 
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minutes before the test began.  The vials were tapped to startle all flies to the 
bottom and then the number of flies climbing up to the top quarter (7cm) of the 
vial within a 15 second period, were counted.  Each vial was used for three 
consecutive measurements, allowing for 5 minutes rest period, with a total of 
~100 flies per treatment group assessed.  This method was designed similarly to 
previous behavioral tests (Ali et al. 2011) (Nichols, Becnel, and Pandey 2012).  
Statistical Analysis 
All data were analyzed using Microsoft Excel and Prism 5 software.  The t-test 
was implemented when comparing just two data groups where significance was 
p-value > .05.  For comparison of multiple groups, ANOVA was used to 
determine significant differences between each group with significance of p-value 
>.05. 
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Results 
Establishment of the CAFÉ assay 
The first set of experiments were designed to test whether flies would consume 
MPTP hydrochloride dissolved in 5% (w/v) sucrose from the capillary.  Typically, 
fruit flies are attracted to sugar containing medium, therefore it remained a 
question to whether there would be an aversion and preference for just the 
sucrose control compared to sucrose containing MPTP hydrochloride.  First, 
green food color was added to each sucrose or MPTP solution in capillary tubes 
for the 24 hour exposure period.  We previously, by spectrophotometry, identified 
the maximal absorbance by spectrophotometry for the green food coloring added 
(Figure 6).  Using the maxima wavelength (630 nm), we compared the amount of 
liquid intake between flies exposed to sucrose or sucrose/MPTP mix.  Figure 7 
shows evaluation of liquid intake, as determined by the amount of green color 
present in sucrose alone (Figure 7A) or sucrose/MPTP mix (Figure 7B) and 
quantitative assessment by absorbance at 630 nm of extracts from whole flies 
after exposure to 5% sucrose or 12 mM MPTP (Figure 7C). There is no visual or 
quantitative difference in liquid consumption.  A secondary assessment was done 
by measuring amount of liquid consumed in a period of 24 hours at 0, 24, or 36 
mM MPTP. Lack of statistical difference among the groups (Figure 8) indicates 
that the level of MPTP is not adverse to the Drosophila melanogaster 
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FIGURE 6 
   
 
 
 
 
 
 
 
 
Figure 6.  Visual spectral analysis of Green Dye 
Maximum absorbance was determined for green dye.  Each absorbance was 
measured by spectrophotometer to determine the wavelength for maximum 
absorbance.   630 nm was the maximum to be used for further consumption 
analysis. 
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FIGURE 7 
 
Figure 7.  Comparison of CAFÉ consumption during exposure to MPTP and 
Sucrose 
Comparison of 5% sucrose and MPTP (36 mM) and just 5% sucrose liquid was 
investigated to determine whether flies were not consuming less of the MPTP 
containing liquid.  Green dye was added to each control and test liquid and 
photos were taken after CAFÉ assay exposure showing consumption of both 
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liquids (A and B).  100 flies were crushed in PBS and absorbance was measured 
at 630 nm in duplicate.  There was no statistical difference found between the 
control (5% sucrose) and test liquid (MPTP with sucrose). 
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FIGURE 8 
 
Figure 8.  Volume consumption in capillary tubes during CAFÉ assay 
exposure 
Further validation of CAFÉ assay exposure with MPTP for the two highest 
concentrations used of MPTP.   No statistical difference was found between the 
control group and either of the exposures (24 mM & 36 mM) (n=5). 
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Assessment of Brain Dopamine Levels after Exposure to MPTP 
In order to determine whether MPTP is toxic to DaN, flies where exposed to 3 
mM, 6 mM, 12 mM, 24 mM, or 36 mM MPTP by the CAFÉ assay.  Brain 
homogenates from the different exposure groups were analyzed via rp-HPLC-
ECD to determine the amount of dopamine per fly brain (n=5).  Figure 9 is a 
representative chromatogram for dopamine analysis indicating the peak for 
dopamine and the internal standard. Levels of dopamine in brain homogenates 
were obtained by comparing the response in the extract to responses obtained 
by known amounts of dopamine. In Figure 10, the amount of dopamine per fly 
brain for each concentration of MPTP is represented with 5% sucrose as control.  
We established that 5% sucrose was suitable for a control because no difference 
in dopamine levels was found when comparing to normal food 24-hour exposure 
(Figure 11). 
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FIGURE 9 
 
 
Figure 9.  Chromatogram profile for Dopamine 
Chromatographic profile for Dopamine and Internal Standard (DBA), detected in 
channels set at 300 mV.  
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FIGURE 10 
 
Figure 10.  Dopamine levels in brain after exposure to MPTP 
Levels of Dopamine represented as picogram (pg) DA per fly brain after CAFÉ 
assay exposure to 3 mM, 6 mM, 12 mM, 24 mM, and 36 mM MPTP in WT male 
flies compared to 5% sucrose as control (A).  Although all groups exposed 
showed a reduction in DA compared to control, 36 mM and 24 mM 
! 44!
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Figure 10.  Dopamine levels in brain after exposure to MPTP 
Levels of Dopamine represented as pictogram (pg) DA per fly brain after CAFÉ 
assay exposure to 3 mM, 6 mM, 12 mM, 24 mM, and 36 mM MPTP in WT male 
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concentrations had the greatest significant difference.  In (B), values are 
expressed as percent DA loss.  The greatest percent loss was seen in 24 and 36 
mM MPTP exposures. Data expressed as mean ±SEM (n=5 ***p< .005 **p<.05)  
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FIGURE 11 
 
Figure 11.  Dopamine levels from 5% sucrose 24-hour exposure compared 
to food control 
Dopamine levels represented as % change when comparing CAFÉ assay 5% 
sucrose exposure vs. normal food control.  No statistical difference was found.  
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 Tyrosine-Hydroxylase labeling in Drosophila brain 
To test whether changes in dopamine levels were due to loss of DaN, we 
performed immunohistochemistry for tyrosine hydroxylase (TH) in fly brains 
exposed to 24 mM MPTP.  Figure 12A shows the confocal images taken from 
sucrose exposed or 24 mM exposed fly brains expressing TH by the Gal-4 driver 
and the quantification of TH-expressing neurons for each group. 
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FIGURE 12 
 
 
Figure 12.  Tyrosine hydroxylase Immunohistochemistry after MPTP 
exposure  
Flies brains expressing GFP labeled Tyrosine Hydroxylase (Green) by the Gal-4 
UAS system compared with rabbit anti-Tyrosine hydroxylase antibody labeling 
(red).  Neurons were counted in sucrose (A and B) control and compared to 
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MPTP exposed flies (C and D).  The average of three separate brain images was 
calculated.  
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 Behavior after exposure to MPTP 
Because motor impairment is a direct symptom of PD and being present in other 
MPTP models, we employed the startle-induced negative geotaxis assay to 
assess whether there was impairment in climbing to MPTP exposed flies 
compared to untreated flies (Figure 13).  Typically, flies without impairment would 
climb towards the light source after being startled to the bottom; therefore most 
flies would climb above 7cm in the conical tube. 
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FIGURE 13 
 
Figure 13.  Startle-Induced Negative geotaxis of MPTP exposed flies 
Behavior analysis of flies after MPTP exposure compared to sucrose control.  
Flies were counted before and after exposure.  Percent flies above 7 cm was 
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determined by counting the number of flies that climbed above 7 cm to the total 
number of flies.  Percent flies above 7 cm increased after exposure to MPTP for 
all exposure, including control when compared to pre-exposure groups (A).  Only 
the 36 mM MPTP dose had a significant increase in climbing activity compared to 
control (B).    
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Discussion 
The MPTP-toxin induced toxicological PD model has never been investigated in 
Drosophila melanogaster.  Until now, there has not been a model method 
reported to expose flies to MPTP.  This may be due to MPTP’s exposure risk 
concern and precautions that are required when used in other animal models.  
The current toxin models (rotenone and paraquat) analyzed in Drosophila do not 
have a complete analysis of Parkinson-like assessments that extend beyond 
behavior and immunohistology, or both.  Here, we show evidence of a reduction 
in dopamine, which is the underlying definition of PD.  Having also looked at 
behavioral analysis, the data is good support for a reduction in dopamine in 
which geotaxis would be expected to decrease, but it should not be the only 
assessment in a model of PD.  Similarly, the indirect analysis of tyrosine 
hydroxylase (the rate-limiting step of dopamine) is not as accurate to determine 
amount of dopamine in the brain. 
Here, we hypothesize that Drosophila which has all the required biological 
components to metabolize MPTP and to accumulate MPP+ in dopamine neurons 
would be susceptible to MPTP(Daneman and Barres 2005).  To reduce exposure 
to lab personnel, we employed the CAFÉ assay to expose Drosophila rather than 
food vial exposure (Ja et al 2007).  Our initial results support the use of this 
approach, as no aversion to the sucrose solution containing MPTP was evident 
(Stafford et al. 2012).  By using a visual indicator, in this case green food dye, we 
compared the consumption amount of sucrose control liquid vs. MPTP liquid at 
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the highest concentration used (Figure 6).  We found no significant difference in 
liquid consumption, when comparing the absorbance of control and exposed flies 
(Figure 7).  In fact, in this case there seemed to be a slight increase in 
absorbance of green dye in flies exposed to MPTP.  In addition, we measured 
the volume consumed in the capillary tubes before and after the CAFÉ assay.  
There was also not a significant difference in the volume consumed based on an 
n=5 (Figure 8). 
 To establish the potential of the MPTP-fly model, groups of flies were 
exposed for 24 hours to increasing concentrations of MPTP (3, 6, 12, 24, or 36 
mM) via the CAFÉ assay.  Figure 9 indicates that brain dopamine levels were 
reduced in all treated groups, except 3mM, after MPTP, when compared to 
sucrose-exposed flies.  We determined that 24 mM and 36 mM led to the largest 
amount of dopamine loss compared to control (Figure 10A).  When shown as 
percent loss of dopamine (Figure 10B), 24 mM and 36 mM MPTP exposure 
leads to a 40-60% dopamine loss, replicating the loss of dopamine in early 
stages PD.  We determined there was no significant difference in dopamine 
using the sucrose CAFÉ exposed flies compared to normal food exposed flies 
(Figure 11).  This difference was a concern based on other feeding studies 
showing variances in transcription due to dietary restriction (Bruce et al. 2013) 
(Ding et al. 2014). 
 Tyrosine hydroxylase (TH), the rate-limiting step in the synthesis of 
dopamine, was visualized to see if there was a deficit in dopamine-containing 
neurons.  After exposure to 24 mM MPTP, TH-GFP expressing neurons by the 
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Gal-4 driver system (green) and co-localized with an antibody to TH (red) were 
counted.  It was expected that a reduction in TH would correlate with loss of 
dopamine as shown in similarly exposed flies seen in the HPLC analysis.  The 
counts seen in the table below the images in Figure 12 show the number of TH 
co-localized neurons counted.  It was found that the MPTP number was lower 
than the sucrose-exposed control, although this was only based on three images 
per group, therefore not enough for statistical analysis. 
 Analysis of behavior did not result with what was expected.  We 
hypothesized that a decrease in dopamine from MPTP exposure would result in 
decreased climbing activity as measure by lower number of flies climbing above 
7 cm (Figure 13).  This hypothesis is based on other studies where drosophila 
were exposed to either paraquat or rotenone and analyzed for geotaxis (Sudati et 
al. 2013) (Jahromi et al. 2013).  Instead, the opposite was observed where there 
was an increase in climbing activity corresponding with increasing exposure to 
MPTP.  Chronic studies with MPTP need to be done to test whether this 
increased motor activity is due to a compensatory mechanism that won’t be 
permanent.  
Conclusions 
In conclusion, the MPTP model in Drosophila melanogaster proposes to be a 
suitable model for future investigation of mechanisms of PD pathology.  This 
model of exposure can be expanded for a wide range of uses for therapeutic 
intervention for idiopathic and familial inherited forms of PD.  
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CHAPTER THREE: AIM TWO 
Correlating the inhibition of mitochondrial Complex I with the loss of the 
dopaminergic system in Drosophila melanogaster:  Measurement of 
mitochondrial complex I activity after dose exposure to MPTP 
Abstract 
Dysfunction of mitochondrial complex I has been set forth as a main hypothesis 
for loss of DaN in PD.  There is reduction in complex I activity in PD patients and 
most used neurotoxins to model PD work by inhibiting mitochondrial complex I.  
Correlating an MPTP-induced death with the inhibition of mitochondrial complex I 
is useful for determining the effectiveness of the model as well as establishing 
the conservation of mechanisms across species.  This chapter looks at the 
verification of MPTP-induced inhibition of mitochondrial complex I. 
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Introduction 
Parkinson's disease is associated with a systemic defect in mitochondrial 
complex I activity. Animal models indicate that exposure to inhibitors of 
mitochondrial complex I, including pesticides, is sufficient to reproduce the 
features of PD, but genetic factors clearly modulate susceptibility. Complex I 
defects may result in oxidative stress and increase the susceptibility of neurons 
to excitotoxic death. In this way, environmental exposures and mitochondrial 
dysfunction may interact and result in neurodegeneration.  One of the major 
discoveries linking mitochondrial complex I with PD was the understanding of the 
toxic mechanism associated with MPTP dopaminergic neuronal loss (Banerjee et 
al. 2009). 
 The MPTP dosing regimen has been used in many animal models 
(excluding Drosophila) and is integral in gathering more information on the 
involvement of mitochondria in PD pathology.  MPTP after crossing the blood-
brain barrier is metabolized to MPP+ by monoamine oxidase B and taken up by 
dopaminergic neurons (DaN) by the dopamine transporter.  Inside DaNs, MPTP 
is accumulated in mitochondria, where it inhibits the oxidation of nicotinamide 
adenine dinucleotide (NAD) substrates by blocking complex I in the electron 
transport chain.  This inhibited oxidation leads to a build-up of reactive oxygen 
species generating damage to macromolecules. 
Evaluating the activity of mitochondrial complex I in an MPTP model is key 
to show the consistency of the model of PD and may allow for the identification of 
a window of susceptibility to test therapeutic interventions to evaluate other 
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environmental exposures that may play a role in sporadic PD.  Additionally, 
establishing a timeline between complex I inhibition and susceptibility of DaN 
may offer major advantage to advance evaluations with PD familial genetics that 
are known to inhibit the mitochondria, such as: DJ-1, LRRK2, PINK-1, and Parkin 
(Lesage and Brice 2012).    
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Materials and Methods 
Chemicals and Reagents 
All reagents used in assessment of mitochondrial complex I activity were 
purchased from Sigma Aldrich (St Louis, MO).   
Fly Stocks 
D. melanogaster wild-type (Canton-S) was obtained from the Bloomington Stock 
center (Bloomington, IN).  The flies were reared on agar medium (1%, w/v 
brewer’s yeast; 2%, w/v sucrose; 1%, w/v agar; 0.08%, v/w Tegosept) at 
constant temperature and humidity (23°C; 60% relative humidity, respectively). 
The flies were reared in 16 x 100 mm vials containing approximately 5 mL of 
medium at constant temperature, humidity (60%) and under 12h dark/light cycle. 
All experiments were performed with the same WT Canton-S strain. 
Fly Exposures 
The capillary feeder method (CAFE) CAFÉ assay used for exposure was 
adapted from JA, et al. 2007.  The exposure model used was similar with two 
chambers.  The inner chamber, containing the flies, was composed of a 25 cm 
vial with perforated lid for air and water exchange from the outer chamber, a 
1000 mL beaker with 20 cm distilled water, and additional holes for capillary tube 
insertion.  Capillary tubes at 40 cm length from World Precision Instruments 
(Sarasota, FL) (cat. #4878) were filled by capillary action with liquid and inserted 
into the inner vial lid with an additional layer of mineral oil to prevent evaporation.  
All exposures (MPTP or sucrose control) were conducted for 24 hours in a 25°C 
room.  After each 24-hour exposure, flies were placed back into isolation vials 
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containing normal food medium for 24 hours before analyses.  All exposures 
were done on 5-10 day old males. 
Protein Preparation 
Mitochondrial and cytosolic proteins were prepared using the mitochondria 
isolation kit from Abcam (Cat# ab110169).  Briefly, brain from approximately 100 
5-10 day-old WT male flies exposed to MPTP or 5% sucrose were dissected and 
homogenized in ice cold isolation buffer containing protein inhibitor cocktail 
(Roche Cat# 04693159001) using a glass dounce homogenizer. Each 
homogenate was centrifuged at 1000xg at 4°C for 10 min. The supernatant was 
then transferred to a new tube, and centrifuged again at 12,000xg at 4°C for 15 
min to separate cytosolic and mitochondria proteins. The supernatant were 
collected as the cytosolic protein sample, while the pellet was washed and re-
suspended in 200µl isolation buffer as the mitochondria protein sample. Protein 
concentration was determined with the BCA protein Assay kit (ThermoFisher, 
Cat# 23225) according to the manufacturer’s suggested protocol. 
Mitochondrial Complex I Activity 
Measurement of complex I activity was modeled after reagent concentrations 
used in (Farge 2002).  Complex I activity was determined by following the 
oxidation of NADH at 340 nm (e=6220 M–1 cm–1) using ubiquinone-1 (coenzyme 
Q10) as the electron acceptor. The assay buffer consisted of 35 mM NaH2PO4 
pH 7.2, 5 mM MgCl2, 2.5 mg/ml BSA, 2 mM KCN, 2 µg/ml antimycin A, 97.5 µM 
ubiquinone, 0.13 mM NADH and 50 µg mitochondrial proteins. Each sample and 
control was done in duplicate in a 96-well assay plate.  Rotenone was added in 
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duplicate to each sample as control for complete mitochondrial complex I 
inhibition. 
Statistical Analysis 
All data were analyzed using Microsoft Excel and Prism 5 software.  For 
comparison of multiple groups, ANOVA was used to determine significant 
differences between each group with significance of p-value >.05. 
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Results 
Mitochondrial Complex I activity in the Drosophila head 
To further explore the impact of MPTP on the dopaminergic system in 
Drosophila, we wanted to quantify the dose in which MPTP inhibits complex I of 
the electron transport chain.  Three doses were chosen based on the dose-
response curve and loss of dopamine as discussed in the previous chapter 
(chapter two).  Figure 14, shows the results of the assessment of complex I to 
reduce NADH in the presence of coenzyme Q10 by the measurement of NADH 
absorbance.  Each exposure group was done in duplicate and normalized to the 
background of NADH. 
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FIGURE 14 
 
Figure 14.  Mitochondrial Complex I activity after MPTP dose exposure 
Absorbance of NADH oxidation was recorded by spectrophotometry at 430 nm.  
Each exposure group was performed in duplicate and measurements were taken 
every minute for 10 minutes.  The higher absorbance indicates more NADH in 
the assay well, due to a lack of activity of mitochondrial complex I.  
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Discussion 
Mitochondrial complex I is the target of MPTP-induced toxicity in dopaminergic 
neurons.  Determining a MPTP dose-induced inhibition of mitochondrial complex 
I is important for examining a dose-susceptibility window.  Here, we measured 
mitochondrial complex I activity with three doses of MPTP (12, 12, and 36 mM) in 
the drosophila MPTP model (Figure 14).  This, to our knowledge, has not been 
done before in this model. 
In Figure 14, we see a dose correlated loss of activity in complex I as measured 
by the absorbance of NADH.  The higher absorbance of NADH is due to the lack 
of oxidation by complex I from its inhibition by MPTP (24 and 36 mM MPTP).  
Whereas, the control group (sucrose) and lower concentration (12 mM MPTP) 
exposure we do not see an inhibition of NADH as determined by a lower 
absorbance.    
Conclusions 
In conclusion, MPTP appears to inhibit complex I in the electron transport chain 
of the mitochondria that was dose-dependent.  Together, the measured damage 
of MPTP, and using a dose above 24 mM proved to affect dopaminergic neurons 
in the brain of Drosophila.  
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APPENDIX A:  
Ogg1 susceptibility to age an MPTP in Drosophila 
Oxidation of the guanine base is the most common form of oxidative stress-
mediated damage to DNA leading to the formation and accumulation of the 
modified guanine lesion 8-hydroxy-2’-deoxyguanosine (oxo8dG). Accumulation 
of Oxo8dG has been linked to increased rate of mutations in dividing cells and 
transcription blockage in post-mitotic cells. High levels of oxo8dG are a common 
finding in affected brain areas in neurodegenerative diseases, particularly in the 
SN of PD patients. Levels of oxo8dG are maintained at bay by the activity of the 
DNA repair enzyme 8-oxoguanine glycosylase 1 (Ogg1).  Mice lacking Ogg1 
have an age-associated loss of the nigrostriatal pathway (Fernando Cardozo-
Pelaez, Sanchez-Contreras, and Nevin 2012).  This neuronal loss resembles 
parkinsonian-like pathology as seen by the specific age-dependent loss of nigral 
dopaminergic neurons as well as the accumulation of ubiquitin-positive inclusions 
in surviving neurons of the nigrostriatal region.  Therefore, the results here 
examine the susceptibility of dopamine in Ogg1 knock-out (Ogg1-/-) flies after 
aging and exposure to MPTP. 
Summary of Method and Results 
WT Canton-S flies or Ogg1 Ogg1-/- flies were exposed to 36 mM MPTP by the 
CAFÉ assay for 24 hours.  After 24 hours, flies were changed to regular food and 
brains were collected another 24 hours after for dopamine analysis (Figure B).  
The dopamine levels were represented as percent loss compared to control, 
where Ogg1-/- showed a higher percent loss compared to WT, indicating they 
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may be more susceptible to MPTP.  In Figure 15A, dopamine was quantified as 
picograms (pg) dopamine per brain.  The same analysis was performed without 
exposure to MPTP, but flies were aged to 80 days. 
 This data is significant showing the drosophila may also have an age-
associated loss of dopamine, similar to results shown in mice.  Also, Ogg1-/- flies 
at a young age seem to be more susceptible to MPTP as expected.  
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FIGURE 15 
 
 
 
 
 
Figure 15.  Ogg1 Dopamine Levels and susceptibility to MPTP 
 
Dopamine level in brain of WT Canton-S flies compared to Ogg1 KO after aging 
for 80 days (A).  The percent dopamine loss was also compared to young WT 
flies and Ogg1 KO at 36 mM MPTP for 24 hours. 
